EGFR and neoplasm: Despite the anti-EGFRvIII activity observed in pre-clinical glioblastoma models,217 dacomitinib-treated recurrent glioblastoma patients with EGFR amplification/EGFRvIII expression had poorer survival outcomes compared with dacomitinib-treated recurrent glioblastoma patients with EGFRvIII negative tumours.218 Likewise, another phase II trial found that EGFRvIII expression in dacomitinib-treated recurrent glioblastoma patients was not associated with any clinical benefit.219